Elopag 50 mg Tablet (Eltrombopag) | Clinical Profile, Price, & Patient Access

Elopag 50 mg is an orally bioavailable, small-molecule thrombopoietin receptor agonist (TPO-RA) containing Eltrombopag. It is specifically engineered to address severe cytopenias by stimulating the proliferation and differentiation of megakaryocytes in the bone marrow. As a high-quality generic equivalent to the innovator brand Promacta (also known as Revolade), Elopag is a cornerstone therapy for Chronic Immune Thrombocytopenia (ITP), Severe Aplastic Anemia (SAA), and thrombocytopenia in Chronic Hepatitis C patients. Unlike treatments that merely slow platelet destruction, Eltrombopag works at the source to prompt the body to produce more platelets naturally.

Expert Commentry on Elopag 50 mg

Uses & Clinical Safety Profile

What exactly is this medication for?

Based on clinical protocols from the FDA, EMA, and NCCN, Eltrombopag is prescribed for several specific conditions:

1. ​Chronic Immune Thrombocytopenia (ITP): For adults and children (1 year and older) who haven’t responded well to corticosteroids or immunoglobulins.
2. ​Chronic Hepatitis C-Associated Thrombocytopenia: To increase platelets so that interferon-based therapy can be started or continued safely.

​Severe Aplastic Anemia (SAA): For patients who haven’t had an insufficient response to immunosuppressive therapy.

Understanding Your Treatment: The Bone Marrow Factory

To understand how Elopag works, think of your bone marrow as a factory and platelets as the product. In conditions like ITP or SAA, the factory is either under attack or running too slowly.

Eltrombopag acts as a “production manager.” It mimics a natural protein called thrombopoietin, binding to specific receptors on the surface of bone marrow cells. This sends a molecular signal (the JAK/STAT pathway) that tells the factory to “speed up” the creation of megakaryocytes—the giant cells that eventually break apart to become the platelets in your bloodstream.

Mechanism & Pharmacokinetics (ADME)

• Absorption: Reaches (C_max) in 2–6 hours. Absorption is highly dependent on an empty stomach.
• Distribution: >99% bound to plasma proteins.
• Metabolism: Primarily hepatic via oxidation (CYP1A2, CYP2C8) and glucuronidation.
• Excretion: Predominantly fecal (59%); Elimination half-life is 21–35 hours.

Administration Protocols: The Strict Rules for Efficacy

Taking Elopag correctly is vital because certain minerals can “trap” the medicine in your gut, preventing it from ever reaching your blood.

• The Empty Stomach Rule: Take Elopag at least 1 hour before or 2 hours after eating.
• The “Cation” Rule: Avoid foods or supplements containing calcium, magnesium, iron, or zinc (milk, yogurt, antacids, or multivitamins) for 4 hours before and 2 hours after your dose.
• Dosage Note: Standard starting dose is 50 mg. However, patients of East or Southeast Asian ancestry usually start at 25 mg, as their bodies process the drug more slowly, leading to higher systemic exposure.

Clinical Safety & Adverse Event Management

The goal of therapy is not to reach a “normal” platelet count, but to maintain a count high enough to prevent bleeding (usually >50,000/µL) while avoiding the risk of blood clots.

Clinical Efficacy & Landmark Trials

• ITP (EXTEND Trial): 86% of patients achieved the target platelet count of ≥ 50,000/μL.
• SAA (Townsley Study): Combining Eltrombopag with standard immunosuppression (IST) resulted in a Complete Response (CR) rate of 58%, a significant leap over IST alone.
• Real-World Evidence (RWE): Post-marketing data confirms that the generic bioequivalence of Elopag provides the same safety profile as the innovator, with consistent marrow stimulation across diverse patient populations.

Drug-Drug Interaction Matrix

Precautions & Special Populations

• Pregnancy: Embryo-fetal toxicity risk. Use effective contraception during and for 7 days after therapy.
• East/Southeast Asian Ancestry: Start at 25 mg once daily.
• Hepatic Impairment: For patients with Cirrhosis (Child-Pugh A, B, C), the starting dose is 25 mg.
• Storage: Store at 20°C to 25°C (68°F to 77°F). No cold-chain required. Protect from moisture in the original container.

Manufacturing Quality Assurance, Global Access, Price & Availability

How Everest Pharmaceutical Ensure WHO-GMP Quality?

Everest Pharmaceutical operates a high-containment oncology and hematology facility. Every batch of Elopag 50 mg undergoes rigorous bioequivalence testing to ensure it mirrors the innovator’s pharmacokinetic Cmax and AUC. Compliance with ISO 9001:2015 and WHO-GMP ensures that the API purity exceeds 99%, providing a safe, accessible therapeutic option.

How To Access Elopag 50 mg Globally Under Named Patient Program (NPP)?

​If Elopag is not available in your local pharmacy, international healthcare guidelines often allow for the legal importation of life-saving medicines for personal use.

• ​Prescription Requirement: A valid, legible prescription from a licensed oncologist or hematologist is mandatory.
• ​Regulatory Compliance: Most national drug authorities allow for the import of a limited supply (typically 3 months) under “Personal Use” or “Named Patient” programs.
• ​Logistics: Always verify with your local customs office regarding specific documentation needed to ensure your life-saving treatment reaches you without delay.

What are the difference between Originator Promacta and Generic Elopag?

Frequently Asked Questions (FAQs)